Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 16/20 | 0.62 |
| ▸ | ERCC5 | P28715 | 2/20 | 0.54 |
| ▸ | FEN1 | P39748 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5130828 | 0.87 | ADORA2B (0.66) | ADORA2BERCC5FEN1CYP1A2CYP3A4 | |
| SCHEMBL18097392 | 0.81 | ADORA2B (0.75) | ADORA2BERCC5FEN1CYP1A2CYP3A4 | |
| SCHEMBL15474256 | 0.81 | ERCC5 (0.72) | ADORA2BERCC5FEN1CYP1A2CYP3A4 | |
| SCHEMBL5129852 | 0.79 | ADORA2B (0.60) | ADORA2BERCC5FEN1CYP1A2CYP3A4 | |
| SCHEMBL4804328 | 0.78 | ADORA2B (0.43) | ADORA2BERCC5FEN1CYP1A2ALDH1A1 | |
| SCHEMBL18080699 | 0.77 | ERCC5 (0.57) | ADORA2BERCC5FEN1CYP1A2CYP3A4 | |
| SCHEMBL18096905 | 0.77 | ADORA2B (1.00) | ADORA2B | |
| SCHEMBL16637896 | 0.76 | ADORA2B (0.69) | ADORA2BERCC5FEN1 | |
| SCHEMBL18097144 | 0.75 | ADORA2B (0.62) | ADORA2BERCC5FEN1CYP1A2CYP3A4 | |
| SCHEMBL18097683 | 0.74 | ERCC5 (0.61) | ADORA2BERCC5FEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989210-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007103776-A2 | A2A ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208040-A1 | e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction | GILEAD PALO ALTO, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208040-A1 | e.g. 3-ethyl-5-methyl-1,3-dihydrothiopheno[2,3-d]pyrimidine-2,4-dione; neurodegenerative disorders, antiischemic agent, antidepressant, attention deficit disorder, hepatic fibrosis, cirrhosis of the liver, and drug addiction | CHRNE, CHRNA3, CHRNA1 | ADORA2B 51/4885ERCC5 4012/4885FEN1 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.